Both humoral and cell mediated immune mechanisms have been implicated in the pathogenesis of rheumatoid synovitis (Yu and Peter, 1974) . Therapeutic response to immunosuppressive drugs such as cyclophosphamide (Cooperating Clinics Committee, 1970) and azathioprine (Urowitz, et al., 1973) and to immunostimulants such as levamisole (Veys and Mielants, 1977) may support this hypothesis.
Thoracic duct drainage has also been successful in the treatment of 12 patients with severe rheumatoid arthritis (Pearson et al., 1975) . We have treated 2 patients with rheumatoid arthritis unresponsive to conventional therapy with external lymphocyte depletion using a continuous cell separator (leucapheresis).
Patients and methods
Case 1 was a 63-year-old Chinese woman with severe, seropositive rheumatoid arthritis of five years' duration. She had been repeatedly admitted to hospital and treated with salicylates, prednisone, gold, chloroquine, azathioprine, and penicillamine. Despite this therapy her disease followed a relentless course, with continuous activity and progressive deformity.
Case 2 was a 41-year-old man with seropositive, nodular rheumatoid arthritis. He had had continuously active disease despite treatment in hospital and intra-articular steroid and gold therapy. Both patients were admitted to hospital for a 2-week control period during which medications Accepted for publication March 13, 1978 Correspondence to Dr M. B. Urowitz, 651A Rheumatic Disease Unit, Wellesley Hospital, 160 Wellesley Street East, Toronto, Canada M4Y 1J3. were stabilised. Case 1 was receiving 3 * 6 g salicylate and 7 5 mg prednisone daily, while case 2 was receiving 4 8 g salicylate daily. These medications were then kept constant throughout the study.
LEUCAPHERESIS PROCEDURE
After obtaining the patients' informed consent leucapheresis was performed with the IBM blood cell separator, model 2990 (International Business Machines, Inc., Endicott, New York) as described previously (Curtis et al., 1972) . From a Teflon cannula in an antecubital vein blood entered the centrifuge. Continuous flow of blood through the centrifuge was maintained at a rate of 50-75 ml per minute. The centrifuge was calibrated to remove leucocytes, primarily lymphocytes (900 rmp). The entire volume of blood depleted of leucocytes was returned to the patient through a cannula inserted in the opposite arm.
In case 1, 19 daily treatments were performed over 6 1/2 weeks. In case 2, 18 daily treatments were performed over 3 1/2 weeks. Each day's treatment was carried out over 3-4 hours. Clinical and laboratory assessments were performed before, on 3 occasions during, and 3 to 7 days after leucapheresis.
CLINICAL ASSESSMENT
The clinical response was assessed by measurement of articular index (Lansbury, 1958) (Singer and Plotz, 1956 ), lupus erythematosus cell preparation (Hargraves, 1954) , ANA by an immunofluorescent test using rat liver or mouse kidney (Friou and Quismorio, 1975) , DNA binding by the Farr technique (Carr et al., 1975) , and complement studies (total haemolytic complement (Mayer, 1961) , and C3 using Immunoplates (Kent Laboratories)). Immunoglobulin levels were also measured by means of immunodiffusion plates (Hyland Laboratories, IgG and TgM; Kallestad Laboratories, IgA).
Immunological methods. Cell mediated immunity was assessed in vivo by skin testing (candida, PPD, SK/SD, and trichophyton). T cells were identified by their capacity to form E rosettes (Jondal et al., 1972) . B cells were identified by the presence of complement receptors (EAC rosettes) (Ross et al., 1973) and immunoglobulins on their surface (Clements et al., 1974) .
The proliferative capacity of lymphocytes was assessed by mitogen stimulation using phytohaemagglutinin (PHA), concanavalin (Con A), and pokeweed mitogen (PWM) in the following way.
Venous blood was collected with phenol-free heparin, and the mononuclear cells were Rheumatoid factor showed a decrease in case 1 (1:1280 to 1:320) but no change in case 2. Immunoglobulin levels showed a slight rise in case 1 and a slight fall in case 2 with a return to pre-leucapheresis levels at the end of therapy. Complement levels remained stable and tests for ANA, LE cells, and DNA binding were persistently negative in both patients.
Immunological studies (Table 2) showed a decrease in total lymphocyte count at the end of leucapheresis. Although the total number of T and B cells fell, the relative proportions were not altered. An initial low responsiveness to concanavalin A increased after treatment. In both cases PHA responsiveness remained unchanged during therapy. A fall from initially normal levels was seen in both patients with pokeweed mitogen.
Skin testing with a variety of antigens demonstrated preservation of response after leucapheresis. In addition, case 1 was able to mount a humoral response when challenged with salmonella antigen before and after therapy.
Daily leucapheresis in case 1 of a mean volume of 7 -1 litres of blood resulted in removal of approximately 1-3 x 109 lymphocytes daily, and in case 2 leucapheresis of a mean volume of 7 3 litres of blood yielded a mean of 2 -03 x 109 lymphocytes daily.
Lymphocytes removed from the centrifuge were examined at intervals. In case 1, 53-76 %Y of lymphocytes removed were T cells and 21-35 % were B cells, approximating their percentage in the circulation. Similarly, case 2 66-83 % were T cells and 11-33 % were B cells. The lymphocyte yield was characteristically higher at the beginning of a week, with a trend toward a lower yield as treatment continued throughout the week.
It is interesting that in case 1 during a holiday period when no leucapheresis was carried out the joint count increased and the 50 ft (15 m) walking time plateaued (see Fig. 1 ). Reinstitution of leucapheresis therapy seemed to recapture the previous response. In case 1 the observed improvement was Side effects from leucapheresis included minor intermittent dizziness and perioral tingling. The decrease in haemoglobin seen in both patients required transfusions in case 1 on 3 occasions. Other previously described complications (Oon and Hobbs, 1975) were not seen in our patients.
Discussion
Some patients with severe rheumatoid arthritis fail to respond to all conventional therapy including cytotoxic drugs. Thoracic duct drainage resulted in improvement in 12 such patients, suggesting that external removal of lymphocytes can result in a remission of symptoms (Pearson et al., 1975) . However, thoracic duct drainage is a major surgical procedure fraught with many potential complications.
External leucocyte depletion has been accomplished by leucapheresis in a small number of disease states. Large numbers ofeosinophils have been removed in a patient with a hypereosinophilic syndrome (Ellman et al., 1974) . In the Sezary Syndrome, a T cell malignancy involving both the circulation and the skin, leucapheresis resulted in a decrease in circulating lymphocytes and in a depletion of lymphocytes from tissue infiltrates (Edelson et al., 1974) .
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We have used this technique in the management of 2 patients with severe rheumatoid arthritis, successfully removing a large number of lymphocytes daily (0 5-3 9 x 109). In the first case a modest clinical improvement and in the second case a marked improvement was documented. This was associated with a decrease in total lymphocyte count, though proportions of T and B cells remained normal. Furthermore, a subnormal response of lymphocytes to concanavalin A improved in both patients during leucapheresis therapy. In 1 patient a rheumatoid nodulewassignificantlyreducedinsizeduringtherapy. A trend to a decrease in rheumatoid factor was seen in 1 patient. Other tests of cell mediated immunity and humoral immunity were not altered.
Both patients have been started on cytotoxic agents and have maintained their level of clinical improvement.
In consequence of the clinical improvement attained in these 2 patients a larger therapeutic trial in patients unresponsive to conventional therapy seems warranted. 
